Cargando…

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab

The treatment of ulcerative colitis has changed over the last decade, with the introduction of biological drugs. This article reviews the currently available therapies for ulcerative colitis and the specific use of these therapies in the management of patients in different settings, particularly the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armuzzi, Alessandro, Pugliese, Daniela, Nardone, Olga Maria, Guidi, Luisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623546/ https://www.ncbi.nlm.nih.gov/pubmed/23630414 http://dx.doi.org/10.2147/DDDT.S33197

Ejemplares similares

Update on the management of inflammatory bowel disease: specific role of adalimumab
por: Guidi, Luisa, et al.
Publicado: (2011)

Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
por: Pugliese, Daniela, et al.
Publicado: (2016)

Mucosal healing in ulcerative colitis: surveillance or colectomy?
por: Andrisani, Gianluca, et al.
Publicado: (2013)

Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab
por: Zeisler, Bella, et al.
Publicado: (2015)

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
por: Freeman, Hugh J
Publicado: (2013)

Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study
por: Pugliese, Daniela, et al.
Publicado: (2018)

Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab
por: Pugliese, Daniela, et al.
Publicado: (2022)

Adherence in ulcerative colitis: an overview
por: Testa, Anna, et al.
Publicado: (2017)

Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
por: Okabayashi, Shinji, et al.
Publicado: (2017)

Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program
por: Loftus, Edward V, et al.
Publicado: (2022)

Atypical Dermatitis Herpetiform and Scalp Psoriasis in Ulcerative Colitis Patient Treated With Adalimumab
por: Alshehri, Hamza, et al.
Publicado: (2023)

A rare case of epiploic appendagitis in a patient affected by ulcerative colitis on vedolizumab therapy
por: Pugliese, Daniela, et al.
Publicado: (2022)

Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
por: Privitera, Giuseppe, et al.
Publicado: (2021)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Treatment of Recalcitrant Pyoderma Gangrenosum with Ulcerative Colitis by Adalimumab Injection
por: Lee, Jin-Hyup, et al.
Publicado: (2017)

Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis
por: Wessman, Laurel L., et al.
Publicado: (2017)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
por: Beilman, Candace L., et al.
Publicado: (2016)

Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
por: Kim, Jae Hyun, et al.
Publicado: (2016)

Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis
por: Hoffmann, Sebastian, et al.
Publicado: (2018)

Reversible Corpus Callosal Lesions Associated with the Use of Adalimumab for Ulcerative Colitis
por: Park, Jin-Woo, et al.
Publicado: (2017)

Ulcerative Tuberculosis in a Patient Treated with Adalimumab
por: VARPULUOMA, Outi, et al.
Publicado: (2022)

Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy
por: Dal Buono, Arianna, et al.
Publicado: (2022)

Medical Management of Ulcerative Colitis with a Specific Focus on 5-Aminosalicylates
por: Freeman, Hugh James
Publicado: (2012)

Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
por: Privitera, Giuseppe, et al.
Publicado: (2021)

Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy
por: Mizoshita, Tsutomu, et al.
Publicado: (2017)

Management of ulcerative colitis
por: Fell, John M, et al.
Publicado: (2016)

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2013)

Efficacy of infliximab and adalimumab therapy in very early onset, severe ulcerative colitis
por: Rohani, Pejman, et al.
Publicado: (2021)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine
por: Nanda, Kavinderjit, et al.
Publicado: (2012)

Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management
por: Terrin, Maria, et al.
Publicado: (2023)

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis
por: Savelkoul, Edo H J, et al.
Publicado: (2022)

Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis?
por: Fairhurst, Natalie Grace, et al.
Publicado: (2018)

Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus
por: Daperno, Marco, et al.
Publicado: (2019)

Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008)

Dramatic improvement of severe acne pustolosa after adalimumab in a patient with ulcerative colitis
por: Rispo, Antonio, et al.
Publicado: (2016)

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
por: Midha, Vandana, et al.
Publicado: (2018)

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring
por: Wasserbauer, Martin, et al.
Publicado: (2022)

Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib
por: Chimenti, Maria Sole, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7prrafboo1unbns2c5hdm1jsut